Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis
Semaglutide produced substantial weight loss in psychiatric patients struggling with antipsychotic-related weight gain, a genuine clinical challenge.
This network meta-analysis pooled 9 RCTs (n=595, predominantly schizophrenia) comparing GLP-1 receptor agonists for weight management in psychiatric patients with comorbid obesity, finding semaglutide QW produced the greatest weight loss (SMD -2.1) versus control with significant metabolic improvements. The estimate carries uncertainty due to sparse indirect networks and heterogeneity, but the magnitude favors semaglutide as the preferred option for antipsychotic-associated weight gain.
What the study was
- Study design
- network_meta_analysis
- Category
- cardiovascular_metabolic
- Maturity
- Potentially Practice-Changing
- Journal
- Transl Psychiatry
Why it surfaced
First NMA addressing GLP-1 RA comparative effectiveness in psychiatric patients with obesity; addresses critical gap in schizophrenia metabolic management; semaglutide result immediately actionable; Nature portfolio journal quality.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.